Interestingly, 2,5-DHBA downregulated these genes’ expression, particularly CCL2, suggesting that the CCL2-CCR2 axis may be a key target for 2,5-DHBA in mitigating MASLD. Here, CCR2 is linked to metabolic dysfunction-associated steatotic liver disease.